Mashup Score:37
ascopost.com# oncology
Mashup Score:18
OncLiveFDA Approves Sacituzumab Govitecan for Pretreated HR+/HER2– Metastatic Breast Cancer - 4 days
Mashup Score:18
The FDA has approved sacituzumab govitecan-hziy (Trodelvy) for the treatment of adult patients with unresectable locally advanced or metastatic hormone receptor–positive, HER2-negative breast cancer...
-
BREAKING: @US_FDA Approves Sacituzumab Govitecan for Pretreated HR+/HER2– Metastatic Breast Cancer #bcsm #oncology https://t.co/n4ZkhKiFB0 https://t.co/n4ZkhKiFB0 - view on twitter
Mashup Score:14
Esmo OpenPrecision medicine in early breast cancer—beginning of a successful story? - 1 week
Mashup Score:14
Over the past 20 years, advances in genomic characterization of breast cancer enabled the constant evolution of clinically relevant subtypes from immunohistochemically defined groups,...
-
Proud to present another paper in a series of publications with high clinical relevance in #oncology in @ESMO_Open: #Precision medicine in early #breastcancer—beginning of a successful story? https://t.co/mTCtajXLoq - view on twitter
Mashup Score:12
OncLiveMridula George, MD, discusses the methods used to evaluate cardiotoxicity associated with adjuvant trastuzumab emtansine plus concurrent radiation therapy, and explains implications on the...
-
Adjuvant trastuzumab emtansine plus concurrent radiation therapy did not result in cardiotoxicities in patients with early-stage HER2-positive breast cancer. @MridulaGeorgeMD @RWJBarnabas #bcsm #oncology https://t.co/Id3kQqgT9D https://t.co/Id3kQqgT9D - view on twitter
Mashup Score:9
OncLiveImmunotherapy Propels Urothelial Carcinoma Treatment Advances - 5 days
Mashup Score:9
Stephanie A. Berg, DO, discussed the implications of these findings on the urothelial cancer treatment paradigm and how updated results may further influence the...
-
Immunotherapy Propels Urothelial Carcinoma Treatment Advances @bergsa83 @DanaFarber #oncology #medtwitter https://t.co/ppwU4exk32 - view on twitter
Mashup Score:8
UROonco23What to expect at the first-ever UROonco23? – UROonco23 - 4 days
Mashup Score:8
Join the first European onco-urology event, UROonco23 in Gothenburg, Sweden from June 30 to July 2, 2023. Get updates on genitourinary (GU) cancers from...
-
In an interview, ESOU Chair Prof. Morgan Rouprêt (FR) shares details about the first-ever #UROonco meeting, to be held in Gothenburg, Sweden from 30 June - 2 July 2023. @MRoupret #ProstateCancer #BladderCancer, #RCC #Oncology Read the article here 👇 https://t.co/XMHsXYRuB4 - view on twitter
2023 ASCO Gastrointestinal Cancers Symposium Filippo Pietrantonio, MD, of Italy’s Istituto Nazionale dei Tumori, discusses phase II results from the INFINITY trial of tremelimumab...
-
Filippo Pietrantonio, MD, on Gastric or Gastroesophageal Junction Adenocarcinoma: Recent Data on Treatment With Tremelimumab and Durvalumab https://t.co/4mCFmINWYM #GEJCancer #stcsm #oncology #gastriccancer #GI23 @FilippoPietran4 - view on twitter
Mashup Score:8
OncLiveNeoadjuvant Pembrolizumab Elicits Deep Responses in Localized MSI-H/dMMR Solid Tumors - 1 week
Mashup Score:8
Neoadjuvant pembrolizumab was found to have high clinical activity and an acceptable safety profile in patients with localized microsatellite instability–high/deficient mismatch repair solid...
-
Neoadjuvant Pembrolizumab Elicits Deep Responses in Localized MSI-H/dMMR Solid Tumors @MDAndersonNews @JCO_ASCO #oncology #MedTwitter https://t.co/hUZmQlPoFw - view on twitter
Mashup Score:8
OncLiveKEYNOTE-991 Trial of Pembrolizumab Plus Enzalutamide/ADT in mHSPC to Stop for Futility - 1 week
Mashup Score:8
Merck is discontinuing the phase 3 KEYNOTE-991 trial evaluating pembrolizumab plus enzalutamide and androgen deprivation therapy vs placebo plus enzalutamide/ADT in patients with metastatic...
-
Merck is discontinuing the phase 3 KEYNOTE-991 trial evaluating pembrolizumab plus enzalutamide and androgen deprivation therapy vs placebo plus enzalutamide/ADT in patients with metastatic hormone-sensitive prostate cancer due to futility. #pcsm #oncology https://t.co/H4O4P0WVwn https://t.co/H4O4P0WVwn - view on twitter
Mashup Score:8
OncLiveMutation Status Drives PARP Inhibitor Investigation and Treatment in mCRPC - 2 days
Mashup Score:8
Atish D. Choudhury, MD, PhD, discussed the significance of these trials within the metastatic castration-resistant prostate cancer treatment landscape, highlighted investigative PARP inhibitor combinations,...
-
PARP inhibitors as monotherapies or in combination with AR pathway inhibitors may broaden treatment options for patients with mCRPC) with gene alterations within the homologous recombination–deficient pathwa. @DanaFarber #pcsm #oncology https://t.co/rr5t2dPC03 https://t.co/rr5t2dPC03 - view on twitter
By The ASCO Post Staff Posted: 2/3/2023 12:22:00 PM Last Updated: 2/3/2023 12:39:23 PM On February 3, the U.S. Food and Drug Administration (FDA)...
.@US_FDA Approves Sacituzumab Govitecan-hziy for Pretreated Patients With HR-Positive, HER2-Negative Breast Cancer https://t.co/GsgiIs4rd4 #bcsm #breastcancer #oncology @FDAOncology - view on twitter